MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - December 21, 2011) - MorphoSys AG /
MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
phase 1b clinical trial evaluating MOR103, a human monoclonal antibody to
(granulocyte macrophage-colony stimulating factor), in patients with
sclerosis (MS) is now open for enrollment, thereby adding a second
the development program. A phase 1b/2a trial in patients with active
arthritis is ongoing and is on track to report data by mid of
Additionally, a phase 1 pharmacokinetic (PK) study in healthy
evaluate a subcutaneous formulation of MOR103 will commence shortly.
"Our proprietary portfolio has made significant progress this year,"
Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "These
studies further increase the value of our lead proprietary drug MOR103.
is strongly implicated in the pathogenesis of inflammatory diseases,
rheumatoid arthritis and multiple sclerosis. Recent in vivo data
animal models for MS demonstrate that inhibition of GM-CSF improves
scores, which further substantiates the decision to choose MS as the
indication for MOR103. My team and I are thus very excited that the
study in multiple sclerosis has been initiated."
The phase 1b dose-escalation study in multiple sclerosis will
safety of three doses of MOR103. In total, 30 patients will be enrolled
study which is planned to be conducted at sites in Germany, the UK and
Data for this trial is expected to be available in 2013.
The PK study will evaluate the pharmacokinetics, bioavailability,
tolerability of subcutaneously administered MOR103 in 32 healthy
Subcutaneous injection represents a more convenient way of
patients and the data will help guide dosing regimens for future clinical
for MOR103. Enrollment for this trial is expected to be completed in 2012.
MorphoSys developed HuCAL, the most successful antibody library
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of
antibodies, one of the fastest-growing drug classes in human
company's AbD Serotec unit uses HuCAL and other antibody
generate superior monoclonal antibodies for research and
Together with its pharmaceutical partners, MorphoSys has
therapeuticpipeline of more than 70 human antibody drug candidates
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
a few. With its ongoing commitment to new antibody technology and
development, MorphoSys is focused on making the healthcare products of
MorphoSys is listed on the Frankfurt Stock Exchange under the symbol
regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
arYla® are registered trademarks of MorphoSys. Ylanthia® and 100
high potentials™ are trademarks of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE